|Anemia and the Low-risk MDS Patient: The Current Landscape and Future Directions|
Shyamala C. Navada, MD, MSCR
|Release Date: March 09, 2020|
Expiration Date: March 09, 2021
Anemia is the most common cytopenia in patients with lower-risk MDS. In this activity, Dr. Shyamala Navada describes this impact on outcomes and prognosis of patients while also identifying therapeutic strategies for treating anemia which aim to reduce transfusion burden. She will also review the investigational agents currently in clinical development that are likely to provide new options for lower-risk MDS.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Astex Pharmaceuticals, Celgene Corporation, and Takeda Oncology.
|Begin, Earn CreditView Only, No Credit|